Fig. 1.

Time course of CT imaging, immunosuppressive therapy, and changes in serum levels of ALT and Cr. (a) Chest CT on day 124 after discontinuation of nivolumab. Slight but diffuse ground‐glass opacities in the bilateral lungs were observed. (b) Chest CT on day 142 after discontinuation of nivolumab. Worsening of ground‐glass opacities in the bilateral lung was observed. (c) Time course of immunosuppressive therapy and changes in serum levels of ALT and Cr. mPSL was started 142 days after discontinuation of nivolumab. After 3 doses of pulse corticosteroid therapy with 500 mg mPSL, PSL (1 mg/kg) was administered with MMF. (d) Chest CT at 43 days after initiation of pulse corticosteroid therapy showed improvement of ground‐glass opacities.